Delivery of biologically active components of heterologous speci

Details Delivery of biologically active components of heterologous speci Delivery of biologically active components of heterologous speci

1982-09-07

1984-07-31

Hazel, Blondel

Drug, bio-affecting and body treating compositions

Lymphokine

435811, A61K 4502

Patent

active

044629850

ABSTRACT:
Interferon glycoprotein isolates of heterologous species origin are subjected to treatment in a digestive environment and non-species-specific biologically active fractions thereof are administered, preferably through digestive tract tissue, to the circulatory system of mammals, including humans, to secure antiviral, antiproliferative (e.g., antineoplastic) and immunomodulatory (e.g., immunopotentiating) effects ordinarily associated only with parenteral administration of homologous species interferon.

REFERENCES:
patent: 3699222 (1972-10-01), Isaacs et al.
patent: 4273703 (1981-06-01), Osther et al.
patent: 4276282 (1981-06-01), Sugimoto et al.
Braude, I. et al., Biochem. Biophys. Res. Comm., vol. 89, pp. 612-619, 1979.
Stewart, W., editor, Interferons and Their Actions, CRC Press Inc., Cleveland, Ohio, pp. 49, 59-64, 1977.

Affiliated with

Also associated with

Rating

Delivery of biologically active components of heterologous speci does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Delivery of biologically active components of heterologous speci, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Delivery of biologically active components of heterologous speci will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-185258